MediciNova concludes subject enrolment in trial of MN-166 [Yahoo! Finance]
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: Yahoo! Finance
The trial randomised 234 participants across two treatment arms at several clinical centres in Canada and the US. Recruitment is now closed. MN-166 is a small molecule orally administered, intended to modulate neuroinflammation and oxidative stress implicated in ALS progression. COMBAT-ALS is a double-blind, randomised, placebo-controlled study with a 12-month blinded phase followed by a six-month open-label extension. The primary efficacy endpoint is the Combined Assessment of Function and Survival (CAFS). Secondary endpoints include the ALS Functional Rating Scale Revised (ALSFRS-R), quality of life evaluations, and muscle strength as measured by hand-held dynamometry. Top-line results are anticipated by the end of next year. Previous studies of MN-166 showed a positive safety profile and indications of treatment response in preclinical models and Phase I/II and Phase II studies. The therapy holds fast track and orphan drug designations from the US Food and Drug Administr
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- Message from the CEO to MediciNova ShareholdersGlobeNewswire
- MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor [Yahoo! Finance]Yahoo! Finance
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorGlobeNewswire
- MediciNova (NASDAQ:MNOV) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MNOV
Earnings
- 11/12/25 - Beat
MNOV
Sec Filings
- 11/12/25 - Form 10-Q
- 10/1/25 - Form EFFECT
- MNOV's page on the SEC website